In oncology, Anlotinib has emerged as a cornerstone product, with 9 indications approved and another 4 indications under NMPA NDA review as of July 2025. Its combination with IO therapies is expanding its reach into first- line treatment for major indications, further unlocking sales potential. The Company's oncology pipeline also contains other promising candidates, such as Culmerciclib, the fastest progressing CDK2/4/6 inhibitor globally, TQB2102, the No.2 ranking HER2 bispecific ADC worldwide, and TQB286 ...